Annals of Surgical Oncology

, Volume 23, Issue 2, pp 546–551 | Cite as

S-1 Adjuvant Chemotherapy Earlier After Surgery Clinically Correlates with Prognostic Factors for Advanced Gastric Cancer

  • Manabu Yamamoto
  • Yoshihisa Sakaguchi
  • Nao Kinjo
  • Shohei Yamaguchi
  • Akinori Egashira
  • Kazuhito Minami
  • Yasuharu Ikeda
  • Masaru Morita
  • Yasushi Toh
  • Takeshi Okamura
Gastrointestinal Oncology



S-1 adjuvant chemotherapy is commonly administered postoperatively for stage II and III advanced gastric cancer.


This study included 113 patients treated with S-1 adjuvant chemotherapy after surgery for stage II and III advanced gastric cancer. These patients were divided into 4 groups: group A (n = 63), who had a longer duration (≥6 months) and earlier S-1 administration (≤6 weeks) after surgery; group B (n = 16), who had a longer and later S-1 administration (>6 weeks) after surgery; group C (n = 27), who had a shorter duration (<6 months) and earlier S-1 administration after surgery; and group D (n = 7), who had a shorter and later S-1 administration after surgery.


The recurrence rates in groups A, B, C, and D were 15.7, 43.8, 44.4, and 57.1 %, respectively (A vs. B, p < 0.05, A vs. C and D, p < 0.01). The survival time of group A was significantly longer than that of other groups (p < 0.005). In addition, the survival time of patients with severe complications was significantly shorter than that of patients with non-severe complications (p < 0.05). An earlier S-1 administration after surgery was the only independent prognostic factor in the multivariate analysis.


The prognosis of advanced gastric cancer was significantly related to the start of S-1 adjuvant treatment within 6 weeks after surgery.


Gastric Cancer Adjuvant Chemotherapy Adjuvant Treatment Advanced Gastric Cancer Pancreatic Fistula 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2001;357:1810–20.CrossRefGoogle Scholar
  2. 2.
    Japanese Gastric Cancer Association. Gastric Cancer Treatment Guideline. 3rd ed. Tokyo, Japan: Kanehara, 2010.Google Scholar
  3. 3.
    Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet. 2005;365:1687–717.CrossRefGoogle Scholar
  4. 4.
    Tancini G, Bonadonna G, Valagussa P, Marchini S, Veronesi U. Adjuvant CMF in breast cancer: comparative 5-year results of 12 versus 6 cycles. J Clin Oncol. 1983;1:2–10.PubMedGoogle Scholar
  5. 5.
    O’Connel MJ, Laurie JA, Kahan M, et al. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol. 1998;16:295–300.Google Scholar
  6. 6.
    Kuebler JP, Wieand HS, O’Connel MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol. 2007;25:2198–204.PubMedCrossRefGoogle Scholar
  7. 7.
    Andre T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as surgical treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27:3109–16.PubMedCrossRefGoogle Scholar
  8. 8.
    Haller DG, Tabernero J, Maroun J, et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol. 2011;29:1465–71.PubMedCrossRefGoogle Scholar
  9. 9.
    Hershman D, Hall MJ, Wang X, Jacobson JS, McBrode R, Grann VR, Neugut AI. Timing of adjuvant chemotherapy initiation after surgery for stage III colon cancer. Cancer. 2006;107:2581–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Biagi JJ, Raphael MJ, Mackillop WJ, Kong W, King WD, Booth CM. Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer. JAMA. 2011;305:2335–42.PubMedCrossRefGoogle Scholar
  11. 11.
    Walker KG, Bell SW, Rickard MJ, Mehanna D, Dent OF, Chapuis PH, Bokey EL. Anastomotic leakage is predictive of diminished survival after potentially curative resection for colorectal cancer. Ann Surg. 2004;240:255–9.PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    McArdle CS, McMillan DC, Hole DJ. Impact of anastomotic leakage on long-term survival of patients undergoing curative resection for colorectal cancer. Br J Surg. 2005;92:1150–4.PubMedCrossRefGoogle Scholar
  13. 13.
    Lerut T, Moons J, Coosemans W, et al. Postoperative complications after transthoracic esophagectomy for cancer of the esophagus and gastroesophageal junction are correlated with early cancer recurrence: role of systemic grading of complications using the modified Clavien classification. Ann Surg. 2009;250:798–807.PubMedCrossRefGoogle Scholar
  14. 14.
    Rizk NP, Bach PB, Schrag D, et al. The impact of complications on outcomes after resection for esophageal and gastroesophageal junction carcinoma. J Am Coll Surg. 2004;198:42–50.PubMedCrossRefGoogle Scholar
  15. 15.
    Sierzega M, Kolodziejczyk P, Kulig J; Polish Gastric Cancer Study Group. Impact of anastomotic leakage on longer-term survival after total gastrectomy for carcinoma of the stomach. Br J Surg. 2010;97:1035–42.PubMedCrossRefGoogle Scholar
  16. 16.
    Yoo HM, Lee HH, Shim JH, Jeon HM, Park CH, Song KY. Negative impact of leakage on survival of patients undergoing curative resection for advanced gastric cancer. J Surg Oncol. 2011;104:734–40.PubMedCrossRefGoogle Scholar
  17. 17.
    Kubota T, Hiki N, Sano T, et al. Prognostic significance of complications after curative surgery for gastric cancer. Ann Surg Oncol. 2014;21:891–8.PubMedCrossRefGoogle Scholar
  18. 18.
    de Melo Gagliato D, Gonzalez-Angulo AM, Lei X, et al. Clinical impact of delaying initiation of adjuvant chemotherapy in patients with breast cancer. J Clin Oncol. 2014;32:735–44.CrossRefGoogle Scholar
  19. 19.
    Japanese Gastric Cancer Association. Japan Classification of Gastric Carcinoma, 14th ed. Japan: Kanehara, 2010.Google Scholar
  20. 20.
    Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Clavien PA, Barkun J, de Oliveira ML, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009;250:187–96.PubMedCrossRefGoogle Scholar
  22. 22.
    Cox DR. Regression models and life tables. J R Stat B. 1972;35:187–220.Google Scholar
  23. 23.
    Sasako M, Sakuramoto S, Katai H, et al. Five-year outcome of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29:4387–93.PubMedCrossRefGoogle Scholar
  24. 24.
    Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst. 1990;82:4–6.PubMedCrossRefGoogle Scholar
  25. 25.
    Fider IJ, Ellis LM. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell. 1994;79:185–8.CrossRefGoogle Scholar
  26. 26.
    Eggermont AM, Steller EP, Sugarbaker PH. Laparotomy enhances intraperitoneal tumor growth and abrogates the antitumor effects of interleukin-2 and lymphokine-activated killer cells. Surgery. 1987;102:71–8.PubMedGoogle Scholar
  27. 27.
    Ono I, Gunji H, Suda K, Iwatsuki K, Kaneko F. Evaluation of cytokines in donor site wound fluids. Scand J Plast Reconstr Surg Hand Surg. 1994;28:269–73.PubMedCrossRefGoogle Scholar
  28. 28.
    Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer. 2004;4:423–36.PubMedCrossRefGoogle Scholar
  29. 29.
    Mimori K, Fukagawa T, Kosaka Y, et al. Hematogenous metastasis in gastric cancer requires isolated tumor cells and expression of vascular endothelial growth factor receptor-1. Clin Cancer Res. 2008;14:2609–16.PubMedCrossRefGoogle Scholar
  30. 30.
    Arigami T, Uenosono Y, Hirata M, Yanagita S, Ishigami S, Natsugoe S. B7-H3 expression in gastric cancer: a novel molecular blood marker for detecting circulating tumor cells. Cancer Sci. 2011;102:1019–24.PubMedCrossRefGoogle Scholar
  31. 31.
    Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454:436–44.PubMedCrossRefGoogle Scholar
  32. 32.
    McMillan DC. Systemic inflammation, nutritional status and survival in patients with cancer. Cur Opin Clin Nutr Metab Care. 2009;12:223–6.CrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2015

Authors and Affiliations

  • Manabu Yamamoto
    • 1
  • Yoshihisa Sakaguchi
    • 2
  • Nao Kinjo
    • 1
  • Shohei Yamaguchi
    • 1
  • Akinori Egashira
    • 1
  • Kazuhito Minami
    • 1
  • Yasuharu Ikeda
    • 1
  • Masaru Morita
    • 1
  • Yasushi Toh
    • 1
  • Takeshi Okamura
    • 1
  1. 1.Department of Gastroenterological SurgeryNational Kyushu Cancer CenterFukuokaJapan
  2. 2.Department of Gastroenterological SurgeryNational Kyushu Medical CenterFukuokaJapan

Personalised recommendations